Takeda's Maribavir Reduces Hospitalization Rates, Hospital Stay In Post-Transplant Infection Patients

  • Takeda Pharmaceutical Co Ltd TAK shared new analyses of Livtencity (maribavir), including additional analyses from Phase 3 SOLSTICE trial data, which supported the FDA approval of Livtencity.
  • Livtencity is approved in the U.S. for patients aged 12 years and above with post-transplant cytomegalovirus (CMV) infection/disease refractory to treatment.
  • Data from an exploratory analysis of the Phase 3 SOLSTICE trial showed that 31.9% of patients treated with Livtencity had at least one hospitalization compared to 36.8% of patients treated with conventional therapies.
  • Also Read: Takeda's Angioedema Drug Shows Promising Action Against COVID-19 Infection.
  • The Livtencity treatment group had a 34.8% reduction over the conventional therapy group (p=0.021). 
  • The length of hospital stay during the treatment phase was 13.27 days/person/year in Livtencity-treated patients compared to 28.73 for those conventionally treated, a 53.8% decrease (p=0.029). 
  • Price Action: TAK shares are down 0.89% at $14.42 during the market session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!